Franklin Genomic Advancem... (HELX)
CBOE: HELX
· Real-Time Price · USD
30.58
0.47 (1.56%)
At close: Sep 11, 2025, 10:09 AM
1.56% (1D)
| Bid | 30.34 |
| Market Cap | 12.65M |
| AUM | 16.85M |
| NAV | 30.64 |
| EPS (ttm) | 1.01 |
| PE Ratio (ttm) | 30.24 |
| Shares Out | 413.7K |
| Inception Date | Feb 25, 2020 |
| Ask | 30.72 |
| Volume | 177 |
| Open | 30.58 |
| Previous Close | 30.11 |
| Day's Range | 30.58 - 30.58 |
| 52-Week Range | 23.74 - 33.69 |
| Holdings | 63 |
| Expense Ratio | 0.50% |
About HELX
Under normal market conditions, the fund invests at least 80% of its net assets in equity securities of companies that are relevant to its investment theme of genomic advancements. The fund invests predominantly in common stock. Although it may invest across economic sectors, the fund concentrates its investments in health care related industries. It is non-diversified.
Asset Class Equity
Ticker Symbol HELX
Inception Date Feb 25, 2020
Provider Franklin Templeton
Website Fund Home Page
Exchange CBOE
Top Sectors
| Sector | Weight % |
|---|---|
| Healthcare | 93.92% |
| Basic Materials | 3.27% |
| Technology | 2.80% |
| Cash & Others | 0.01% |
Top 10 Holdings 40.31% of assets
| Name | Symbol | Weight |
|---|---|---|
| Natera, Inc. | NTRA | 6.31% |
| Alnylam Pharmaceutic... | ALNY | 5.04% |
| Medpace Holdings, In... | MEDP | 4.51% |
| Guardant Health, Inc... | GH | 4.39% |
| Insmed Incorporated | INSM | 4.38% |
| United Therapeutics ... | UTHR | 3.40% |
| Tempus Ai, Inc. | TEM | 3.21% |
| Krystal Biotech, Inc... | KRYS | 3.13% |
| Ligand Pharmaceutica... | LGND | 3.01% |
| Astrazeneca PLC | AZN | 2.93% |
Dividends Dividend Yield 0.24%
| Ex-Dividend | Amount | Payment Date |
|---|---|---|
| Dec 30, 2021 | $0.0039 | Jan 7, 2022 |
| Dec 13, 2021 | $0.1142 | Dec 21, 2021 |
| Dec 14, 2020 | $0.0518 | Dec 23, 2020 |
